Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy aloneTARRYTOWN, N.Y.,…
Conference call to be held Tuesday, February 28, 2023 at 8:30 AM ETNEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) --…
WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy Phase 1 Study of WTX-330 is intended to evaluate the…
Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick…
PHILADELPHIA, PA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its…
If approved, niraparib in combination with abiraterone acetate (AA), will be the first dual action tablet (DAT) available in the European…
Additional interim biomarker and efficacy data from first six patients continue to demonstrate both the high and low dose of…
Administration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 11 years…
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 –…
— Final safety and effectiveness analysis from APeX-S showed ORLADEYO 150 mg resulted in a median attack rate of 0.0…